» Articles » PMID: 36303774

Integrative Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2

Overview
Journal Front Bioinform
Specialty Biology
Date 2022 Oct 28
PMID 36303774
Authors
Affiliations
Soon will be listed here.
Abstract

The ongoing COVID-19 outbreak have posed a significant threat to public health worldwide. Recently Toll-like receptor (TLR) has been proposed to be the drug target of SARS-CoV-2 treatment, the specificity and efficacy of such treatments remain unknown. In the present study we performed the investigation of repurposed drugs via a framework comprising of Search Tool for Interacting Chemicals (STITCH), Kyoto Encyclopedia of Genes and Genomes (KEGG), molecular docking, and virus-host-drug interactome mapping. Chloroquine (CQ) and hydroxychloroquine (HCQ) were utilized as probes to explore the interaction network that is linked to SARS-CoV-2. 47 drug targets were shown to be overlapped with SARS-CoV-2 network and were enriched in TLR signaling pathway. Molecular docking analysis and molecular dynamics simulation determined the direct binding affinity of TLR9 to CQ and HCQ. Furthermore, we established SARS-CoV-2-human-drug protein interaction map and identified the axis of TLR9-ERC1-Nsp13 and TLR9-RIPK1-Nsp12. Therefore, the elucidation of the interactions of SARS-CoV-2 with TLR9 axis will not only provide pivotal insights into SARS-CoV-2 infection and pathogenesis but also improve the treatment against COVID-19.

Citing Articles

Dynamic metabolic modeling of ATP allocation during viral infection.

Lu A, Dukovski I, Segre D bioRxiv. 2024; .

PMID: 39605584 PMC: 11601281. DOI: 10.1101/2024.11.12.623198.


Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.

Calvo-Alvarez E, Dolci M, Perego F, Signorini L, Parapini S, DAlessandro S Microorganisms. 2022; 10(7).

PMID: 35889004 PMC: 9320270. DOI: 10.3390/microorganisms10071284.


A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19.

Ahmed F, Soomro A, Salih A, Samantasinghar A, Asif A, Kang I Biomed Pharmacother. 2022; 153:113350.

PMID: 35777222 PMC: 9236981. DOI: 10.1016/j.biopha.2022.113350.

References
1.
Smoot M, Ono K, Ruscheinski J, Wang P, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2010; 27(3):431-2. PMC: 3031041. DOI: 10.1093/bioinformatics/btq675. View

2.
Cava C, Bertoli G, Castiglioni I . In Silico Discovery of Candidate Drugs against Covid-19. Viruses. 2020; 12(4). PMC: 7232366. DOI: 10.3390/v12040404. View

3.
Khaedir Y, Kartika R . Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19. J Interferon Cytokine Res. 2021; 41(2):37-43. DOI: 10.1089/jir.2020.0135. View

4.
Min Y, Huang M, Sun X, Deng F, Wang H, Ning Y . Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput Struct Biotechnol J. 2021; 19:4217-4225. PMC: 8310780. DOI: 10.1016/j.csbj.2021.07.023. View

5.
Ghazy R, Almaghraby A, Shaaban R, Kamal A, Beshir H, Moursi A . A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci Rep. 2020; 10(1):22139. PMC: 7746770. DOI: 10.1038/s41598-020-77748-x. View